VIDEO | Pfizer Head of Clinical AI/ML: We’re Leveraging Data To Bring Medicines to Patients Rapidly

(US and Canada) Subha Madhavan, Vice President & Head of Clinical AI/ML and Early Clinical Development at Pfizer, speaks with Michael C. Fillios, IT Ally Founder and CEO and CDO Magazine Editorial Board Member, in a video interview about her background, her current role, and clinical intelligence AI/ML use cases.

Madhavan mentions that her fascination with the intersection of science and data goes back to her childhood. She observed her grandfather — a veterinarian — storing details such as addresses and identification of animals in his register.

Madhavan was introduced to data and analytics while leveraging information from a human genome sequencing project for drug development at Johns Hopkins University. She notes that a lot of data-driven decisions and innovations are already happening in oncology.

Regarding AI and ML technology use cases in clinical intelligence, Madhavan says Pfizer leverages digital, data, and precision medicine, among other tools, to bring medication to patients rapidly.

In terms of application, she mentions how AI and ML can help optimize clinical trials and run them more rapidly and accurately in the later development stages. Madhavan points out that Pfizer relies on both internal talent and external companies.

She also highlights an external collaboration for developing advanced artificial intelligence-based disease models.

Concluding, Madhavan says there are many opportunities to apply advanced techniques like machine learning to address and alleviate pain and disease.

CDO Magazine appreciates Subha Madhavan for sharing her insights and data success stories with our global community.